NERX BIOSCIENCES, INC.

Basic Information

212 W 10TH ST STE A480
INDIANAPOLIS, IN, 46202-5608

http://www.nerxbiosciences.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 963580894
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Development of novel lung cancer therapeutics targeting the DNA damage response

    Amount: $249,431.00

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical a ...

    STTR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Development of Novel Agents Targeting Genome Stability and Maintenance for Treati

    Amount: $229,680.00

    DESCRIPTION (provided by applicant): Epithelial ovarian cancer (EOC) is uniformly fatal once resistance to platinum based therapy (Pt) is observed. Innate resistance is observed in approximately 25% o ...

    STTR Phase I 2012 Department of Health and Human Services
  3. Targeting the ERCC1/XPF nuclease for cancer therapy

    Amount: $299,922.00

    DESCRIPTION (provided by applicant): Platinum based agents (Pt) are the most commonly prescribed chemotherapeutics used in the treatment of solid tumors and are part of the curative treatment regimen ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government